Market Overview - The medical device sector increased by 1.13% on November 28, with Kangwei Century leading the gains [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] Top Performers - Kangwei Century (688426) closed at 27.86, up 5.17% with a trading volume of 18,500 lots and a transaction value of 50.42 million [1] - Mindray Medical (300760) closed at 204.01, up 3.93% with a trading volume of 117,800 lots and a transaction value of 2.378 billion [1] - Yingke Medical (300677) closed at 43.07, up 3.71% with a trading volume of 179,300 lots and a transaction value of 761 million [1] Underperformers - Weigao Orthopedics (688161) closed at 29.15, down 2.57% with a trading volume of 14,700 lots and a transaction value of 43.07 million [2] - Danna Biological (920009) closed at 81.75, down 2.21% with a trading volume of 8,252 lots and a transaction value of 67.67 million [2] - Zhonghong Medical (300981) closed at 14.21, down 2.07% with a trading volume of 86,200 lots and a transaction value of 122 million [2] Capital Flow - The medical device sector experienced a net outflow of 173 million from institutional investors, while retail investors saw a net inflow of 15.56 million [2] - The top stocks by net inflow from retail investors included Mindray Medical and Hotgen Biotech, while Zhendong Medical and Haier Biomedical saw significant net outflows [3]

Core Viewpoint - The medical device sector is experiencing significant activity, driven by government initiatives to enhance consumer product supply and promote innovation in health products, particularly in high-end medical devices and wearable technology [1][2]. Group 1: Market Activity - As of November 28, the medical device ETF (562600) rose by 0.23%, reaching a record size of 333 million yuan [1]. - Key stocks in the sector, including Kangwei Century, Mindray Medical (300760), and Yingke Medical (300677), showed positive performance [1]. Group 2: Government Initiatives - Six departments issued a plan to enhance the adaptability of consumer goods supply and demand, focusing on the innovation and development of health products [1]. - The plan emphasizes expanding the supply of specialized and new products, particularly in high-end medical devices and home health management applications [1]. Group 3: Internationalization of Domestic Medical Devices - Huachuang Securities noted that the internationalization of domestic medical device companies is progressing rapidly, with a significant increase in overseas certifications [1]. - According to data from Sullivan, medical devices are expected to account for 43.6% of China's medical device export trade in 2024, indicating a promising outlook for overseas expansion [1]. Group 4: Investment Opportunities - The medical device ETF (562600) tracks the CSI All Index Medical Device Index, which includes 100 representative companies, capturing 89.3% of the medical device industry [2]. - Investors can also consider alternative options such as the Huaxia CSI All Index Medical Device ETF Initiated Link A (021250) and Link C (021251) for convenient investment [2].

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4494.42 points, up 0.15%, with a trading volume of 7.52 billion yuan and a turnover rate of 0.75% [1] - Among the index constituents, 32 stocks rose while 24 fell, with Medical Pulse leading the gainers at 3.65% and Health Road leading the decliners at 3.41% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (14.56% weight, latest price 196.30 yuan, market cap 238 billion yuan, up 1.50%) [1] - Yier Eye Hospital (11.62% weight, latest price 11.40 yuan, market cap 106.31 billion yuan, down 0.26%) [1] - Lejin Medical (4.85% weight, latest price 15.87 yuan, market cap 29.26 billion yuan, up 0.13%) [1] - Aimeike (4.80% weight, latest price 146.26 yuan, market cap 44.26 billion yuan, up 0.83%) [1] - Yuyue Medical (4.66% weight, latest price 35.70 yuan, market cap 35.79 billion yuan, down 0.67%) [1] - Yingke Medical (3.64% weight, latest price 41.53 yuan, market cap 27.21 billion yuan, up 1.94%) [1] - Furuide (3.59% weight, latest price 67.08 yuan, market cap 17.78 billion yuan, up 1.36%) [1] - Meinian Health (3.58% weight, latest price 5.28 yuan, market cap 20.67 billion yuan, down 1.68%) [1] - Sinopharm (3.35% weight, latest price 18.42 yuan, market cap 57.48 billion yuan, down 0.69%) [1] - Ping An Good Doctor (2.63% weight, latest price 13.66 yuan, market cap 29.52 billion yuan, down 1.83%) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 58.83 million yuan, while retail investors saw a net inflow of 78.07 million yuan [1] - Specific stock capital flows include: - Aimeike: Main fund net inflow of 46.99 million yuan, retail net outflow of 30.07 million yuan [2] - Mindray Medical: Main fund net inflow of 33.08 million yuan, retail net outflow of 17.11 million yuan [2] - Furuide: Main fund net inflow of 13.68 million yuan, retail net outflow of 19.08 million yuan [2] Recent Adjustments - The Shenzhen-Hong Kong Medical Index has undergone adjustments in the last 10 days, with one new stock added [2]

Core Insights - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4391.58 points, up 0.14%, with a trading volume of HKD 8.259 billion and a turnover rate of 0.75% [1] - Among the index constituents, 32 stocks rose while 24 fell, with Mai Rui Medical leading the gainers at 3.65% and Jian Kang Zhi Lu leading the decliners at 3.41% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index are as follows: - Mai Rui Medical (sz300760) holds a weight of 14.56%, latest price at HKD 196.30, with a market cap of HKD 238 billion and a gain of 1.50% [1] - Yan Er Eye Hospital (sz300015) has a weight of 11.62%, latest price at HKD 11.40, with a market cap of HKD 106.31 billion and a decline of 0.26% [1] - Le Jin Medical (sz300003) has a weight of 4.85%, latest price at HKD 15.87, with a market cap of HKD 2.93 billion and a slight gain of 0.13% [1] - Ai Mei Ke (sz300896) has a weight of 4.80%, latest price at HKD 146.26, with a market cap of HKD 44.26 billion and a gain of 0.83% [1] - Yu Yue Medical (sz002223) has a weight of 4.66%, latest price at HKD 35.70, with a market cap of HKD 35.79 billion and a decline of 0.67% [1] - Ying Ke Medical (sz300677) has a weight of 3.64%, latest price at HKD 41.53, with a market cap of HKD 27.21 billion and a gain of 1.94% [1] - Fu Rui Co., Ltd. (sz300049) has a weight of 3.59%, latest price at HKD 67.08, with a market cap of HKD 17.78 billion and a gain of 1.36% [1] - Mei Nian Health (sz002044) has a weight of 3.58%, latest price at HKD 5.28, with a market cap of HKD 20.67 billion and a decline of 1.68% [1] - China National Pharmaceutical (hk01099) has a weight of 3.35%, latest price at HKD 18.42, with a market cap of HKD 57.48 billion and a decline of 0.69% [1] - Ping An Good Doctor (hk01833) has a weight of 2.63%, latest price at HKD 13.66, with a market cap of HKD 29.52 billion and a decline of 1.83% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled HKD 58.83 million, while retail investors saw a net inflow of HKD 78.07 million [1] - The detailed capital flow for the top stocks shows: - Ai Mei Ke (300896) had a main fund net inflow of HKD 46.99 million but a retail net outflow of HKD 30.07 million [2] - Mai Rui Medical (300760) experienced a main fund net inflow of HKD 33.08 million with retail outflows [2] - Other stocks like Fu Rui Co., Ltd. (300049) and Li Bang Instruments (300206) also showed mixed capital flows with net inflows from main funds but outflows from retail investors [2] Recent Adjustments - In the past 10 days, there has been an adjustment in the Shenzhen-Hong Kong Stock Connect Medical Index, with one new stock added [2]

| 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅%。 | | --- | --- | --- | --- | --- | --- | | 002162 | 悦心健康 | 章 | 9.94 | 48.84亿 | 53.47 | | 300300 | 海峡创新 | + | 5.31 | 91.29亿 | 375.35 | | 600735 | ST新华锦 | | 5.03 | 26.88亿 | 37.50 | | 300632 | 光莆股份 | + | 4.83 | 45.75亿 | 36.15 | | 301187 | 欧圣电气 | | 3.95 | 63.76亿 | 4.61 | | 600748 | 上实发展 | | 3.69 | 114亿 | 71.67 | | 300562 | 乐心医疗 | → | 3.45 | 32.11亿 | 0.60 | | 301337 | 小夜中子 | | 3.35 | 33.09亿 | 9.14 | | 002614 | 奥佳花 | | 2.87 | 46.95亿 | 15.49 | | 002105 | 信隆健康 | 资 | 2.67 | 26.87亿 ...

【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不 对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担 全部责任。邮箱：news_center@staff.hexun.com 国信证券研报指出，英科医疗25Q3收入同比微降，表明一次性手套行业价格仍处历史较低区间；归母 净利润同比大增，主要得益于去年同期低基数及本期金融资产公允价值变动收益等非经常性损益贡献。 一次性手套行业供需格局有望持续优化，叠加公司产能规模扩张与产线升级，成本控制与盈利能力有望 进一步增强。公司作为龙头企业，凭借规模化生产优势、全产业链布局及全球化渠道网络，有望进一步 提升全球市场份额。综合绝对估值与相对估值，公司价格区间为44.07-48.59元，对应市值区间为289- 318亿元，较当前股价有14-26%溢价空间，首次覆盖，给予"优于大市"评级。 ...

Macro and Strategy - The macroeconomic review highlights that the U.S. non-farm payrolls increased by 119,000 in September, significantly above the expected 50,000, with the unemployment rate slightly rising to 4.4% [7] Industry and Company - In the restaurant industry, the report recommends leading companies in the hot pot sector, noting that in October 2025, the A-share, H-share, and U.S. stock markets saw significant gains for several chain restaurants, particularly Guoquan, which projected a revenue increase of 13.6%-25.8% for Q3 2025 [3][8] - The report indicates that the overall restaurant revenue in China increased by 3.8% year-on-year in October, with the CPI showing a slight increase due to holiday effects and domestic demand policies [8] - The report tracks the expansion of coffee brands, with notable growth in the coffee sector, particularly for brands like Nuo Wa, which saw significant store openings [9] - For the home appliance industry, October sales were under pressure, with a 15% decline in retail sales of home appliances, and a 13% drop in export value [13][14] - The report notes that in October, air conditioning sales fell by 20.1%, with expectations of continued pressure on production in December [15] - In the automotive sector, XPeng Motors reported a 149% year-on-year increase in sales for Q3 2025, with total revenue reaching 20.4 billion yuan, marking a 102% increase [19][20] - The report highlights that NVIDIA's revenue for Q3 reached $57 billion, a 62% year-on-year increase, driven by strong demand in data centers and gaming [25][26] - NetEase's revenue for Q3 increased by 8% year-on-year, with deferred revenue growing by 25%, indicating strong long-term operational capabilities [28][30] - Huazhu Group's Q3 revenue grew by 17.5% year-on-year, with a focus on expanding its membership base and improving revenue management [31][32] - Ctrip's Q3 revenue increased by 15.5% year-on-year, with a significant contribution from the sale of Makemytrip, indicating strong performance in the travel sector [34]

Core Points - The stock price of Yingke Medical (300677) closed at 40.18 yuan on November 24, 2025, marking a 4.17% increase from the previous trading day, with a total market capitalization of 26.31 billion yuan [1] - The company announced the completion of the registration for the reserved portion of its 2025 restricted stock incentive plan, with the grant date set for October 15, 2025, and the listing date on November 26, 2025 [1] - A total of 370,000 shares were granted at a price of 11.25 yuan per share to two senior executives, including the board director and general manager Chen Qiong, and the board vice president Yu Haisheng [1] - Following this grant, the total share capital of the company will increase to 655,163,743 shares, with the incentive plan having four unlock periods corresponding to performance targets from 2026 to 2029, including revenue and net profit metrics [1]

证券日报网讯 11月24日晚间，英科医疗发布公告称，公司完成了2025年限制性股票激励计划预留部分 的限制性股票的授予登记工作。本次授予的限制性股票上市日期为：2025年11月26日；本次授予的限制 性股票登记数量：37.00万股；限制性股票授予价格：11.25元/股；本次授予的限制性股票授予登记人 数：2名；本次授予的限制性股票来源：公司向激励对象定向发行的公司A股普通股股票。 （文章来源：证券日报） ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-157 英科医疗科技股份有限公司 关于公司 2025 年限制性股票激励计划预留授予登记 重要内容提示： 1、本次授予的限制性股票上市日期为：2025 年 11 月 26 日 2、本次授予的限制性股票登记数量：37.00 万股 3、限制性股票授予价格：11.25 元/股 4、本次授予的限制性股票授予登记人数：2 名 5、本次授予的限制性股票来源：公司向激励对象定向发行的公司 A 股普通股股票 根据中国证券监督管理委员会《上市公司股权激励管理办法》（以 下称"《管理办法》"）、深圳证券交易所、中国证券登记结算有限责 任公司深圳分公司的有关规定，英科医疗科技股份有限公司（以下简 称"公司"）完成了2025年限制性股票激励计划（以下简称"本次激励 计划"）预留部分的限制性股票的授予登记工作，现将有关情况公告 如下： 完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 （一）2025年5月29日，公司召开第四届董事会第五次会议和第 四届监事会第五次会议，审议通过了《关于公司<2025年限制性股票 激 ...